TrivarX Limited (AU:TRI)
ASX:TRI
Want to see AU:TRI full AI Analyst Report?
TRI Stock Chart & Stats
AU$0.02
<AU$0.01(6.67%)
At close: 4:00 PM EST
AU$0.02
<AU$0.01(6.67%)
Day’s Range― - ―
52-Week Range<AU$0.01 - AU$0.04
Previous CloseN/A
Volume87.40K
Average Volume (3M)1.22M
Market Cap
AU$32.30M
Enterprise ValueAU$27.76M
Total Cash (Recent Filing)AU$1.25M
Total Debt (Recent Filing)AU$169.03K
Price to Earnings (P/E)―
Beta2.72
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.00
Shares Outstanding1,153,693,500
10 Day Avg. Volume1,871,965
30 Day Avg. Volume1,217,195
Financial Highlights & Ratios
PEG Ratio0.23
Price to Book (P/B)0.82
Price to Sales (P/S)0.00
P/FCF Ratio-54.76
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetAn extremely low debt-to-equity ratio and a multi-million equity cushion materially reduce financial distress risk and extend strategic optionality. This durable capital base supports continued product development or clinical/market activities despite operating losses, improving survival odds.
Improving Cash BurnA marked year-over-year reduction in free cash flow outflow signals tighter cost control and more disciplined resource allocation. Sustained lower burn is a structural positive, lengthening runway and reducing near-term financing needs while management works toward a commercial revenue model.
Lean Operating StructureA very small headcount implies low fixed payroll overhead and operational leverage that can preserve capital while developing product-market fit. For an early-stage healthcare information services firm, a lean team supports capital efficiency and slower cash depletion absent revenue.
Bears Say
Zero Reported RevenueHaving no reported revenue is a fundamental constraint: it prevents assessment of demand, unit economics, or scalable margins. Over a multi-month horizon this raises execution risk, as the company must demonstrate commercial adoption before losses can be sustainably reversed.
Sustained Net LossesRepeated annual losses indicate the core business is not yet self-sustaining. Continued negative profitability erodes returns and forces reliance on new capital for operations and growth, which can dilute existing shareholders and constrain long-term investment in product and regulatory efforts.
Negative Operating Cash FlowNegative operating cash flow shows losses are translating into real cash outflows, limiting internal funding for commercialization or clinical validation. Unless cash generation reverses, management will need external financing, increasing execution risk and potential dilution over the medium term.
TrivarX Limited News
TRI FAQ
What was TrivarX Limited’s price range in the past 12 months?
TrivarX Limited lowest share price was <AU$0.01 and its highest was AU$0.04 in the past 12 months.
What is TrivarX Limited’s market cap?
TrivarX Limited’s market cap is AU$32.30M.
When is TrivarX Limited’s upcoming earnings report date?
TrivarX Limited’s upcoming earnings report date is Aug 27, 2026 which is in 79 days.
How were TrivarX Limited’s earnings last quarter?
TrivarX Limited released its earnings results on Feb 24, 2026. The company reported -AU$0.002 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.002.
Is TrivarX Limited overvalued?
According to Wall Street analysts TrivarX Limited’s price is currently Overvalued.
Does TrivarX Limited pay dividends?
TrivarX Limited does not currently pay dividends.
What is TrivarX Limited’s EPS estimate?
TrivarX Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does TrivarX Limited have?
TrivarX Limited has 1,153,693,500 shares outstanding.
What happened to TrivarX Limited’s price movement after its last earnings report?
TrivarX Limited reported an EPS of -AU$0.002 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -8.696%.
Which hedge fund is a major shareholder of TrivarX Limited?
Currently, no hedge funds are holding shares in AU:TRI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
TrivarX Limited Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Fundamentals
Return on Equity
-7.84%
Trailing 12-Months
Asset Growth
112.47%
Trailing 12-Months
Company Description
TrivarX Limited
Operating as a health technology enterprise, TrivarX Limited specializes in crafting artificial intelligence-driven, scientifically validated instruments designed for the assessment and identification of behavioral health disorders. Its market presence extends across Australia and the United States. The company delivers mental well-being provisions tailored for corporate clients through its enterprise health offerings, concurrently developing solutions for medical service providers. Established in 1987, the entity was formerly known as Medibio Limited until its rebranding as TrivarX Limited in October 2023. Its principal place of business is situated in Mount Lawley, Australia.
Technical Analysis
Resonance Health Ltd
―
Opyl Ltd.
―
MedAdvisor Limited
―
InteliCare Holdings Limited
―
PainChek Ltd
―
Options Prices
Currently, No data available
---